{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:33:33Z","timestamp":1793316813161,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kidney fibrosis and fibrogenesis significantly exacerbate chronic kidney disease (CKD) progression and are essential therapeutic targets. Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM). Several studies have demonstrated that BZM attenuates renal impairment in patients with MM, although this effect is generally considered to be the result of MM remission. Recently, several studies on BZM reported anti-fibrotic effects on liver and skin in experimental animal models. However, its effect on renal fibrosis has yet to be examined. Here, we investigated the anti-fibrotic effects of BZM in an experimental mouse model of fibrosis that uses aristolochic acid I (AA). Ten weeks of AA administration with BZM treatment twice a week significantly attenuated AA-induced renal dysfunction and albuminuria, reduced the expression of renal fibrosis-related proteins and kidney injury markers, such as \u03b1SMA, Kim1, and Ngal, and prevented renal fibrosis at the level of histopathology. Furthermore, pathological activation of TGF\u03b21-Smad3 signaling and apoptosis, essential pathophysiological causes of AA-induced nephropathy (AAN), were ameliorated by BZM, suggesting this mechanism may be involved in improving fibrosis in AAN. In conclusion, BZM directly inhibits renal fibrosis in CKD via suppression of TGF\u03b21-Smad3 signaling and is promising in terms of drug repositioning.<\/jats:p>","DOI":"10.1038\/s41598-017-13486-x","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T14:10:33Z","timestamp":1507299033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-\u03b21"],"prefix":"10.1038","volume":"7","author":[{"given":"Moko","family":"Zeniya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Yui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Chiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Sohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatemitsu","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"13486_CR1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1172\/JCI72267","volume":"124","author":"JS Duffield","year":"2014","unstructured":"Duffield, J. S. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest \n                           124, 2299\u20132306, https:\/\/doi.org\/10.1172\/JCI72267 (2014).","journal-title":"J Clin Invest"},{"key":"13486_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","volume":"20","author":"KA Nath","year":"1992","unstructured":"Nath, K. A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis \n                           20, 1\u201317 (1992).","journal-title":"Am J Kidney Dis"},{"key":"13486_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0046-8177(70)80060-0","volume":"1","author":"GE Striker","year":"1970","unstructured":"Striker, G. E., Schainuck, L. I., Cutler, R. E. & Benditt, E. P. Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol \n                           1, 615\u2013630 (1970).","journal-title":"Hum Pathol"},{"key":"13486_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(68)90589-8","volume":"2","author":"RA Risdon","year":"1968","unstructured":"Risdon, R. A., Sloper, J. C. & De Wardener, H. E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet \n                           2, 363\u2013366 (1968).","journal-title":"Lancet"},{"key":"13486_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","volume":"88","author":"C Cohen","year":"2015","unstructured":"Cohen, C. et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int \n                           88, 1135\u20131143, https:\/\/doi.org\/10.1038\/ki.2015.201 (2015).","journal-title":"Kidney Int"},{"key":"13486_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.24035","volume":"90","author":"BA Zannetti","year":"2015","unstructured":"Zannetti, B. A. et al. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol \n                           90, 647\u2013652, https:\/\/doi.org\/10.1002\/ajh.24035 (2015).","journal-title":"Am J Hematol"},{"key":"13486_CR7","first-page":"148","volume":"105","author":"F Ward","year":"2012","unstructured":"Ward, F. et al. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy. Ir Med J \n                           105, 148\u2013149 (2012).","journal-title":"Ir Med J"},{"key":"13486_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol \n                           34, 1544\u20131557, https:\/\/doi.org\/10.1200\/JCO.2015.65.0044 (2016).","journal-title":"J Clin Oncol"},{"key":"13486_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10753-011-9380-y","volume":"35","author":"SS Koca","year":"2012","unstructured":"Koca, S. S. et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation \n                           35, 810\u2013817, https:\/\/doi.org\/10.1007\/s10753-011-9380-y (2012).","journal-title":"Inflammation"},{"key":"13486_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00535-012-0675-z","volume":"48","author":"I Saeki","year":"2013","unstructured":"Saeki, I. et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol \n                           48, 738\u2013750, https:\/\/doi.org\/10.1007\/s00535-012-0675-z (2013).","journal-title":"J Gastroenterol"},{"key":"13486_CR11","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","volume":"194","author":"TP Chang","year":"2015","unstructured":"Chang, T. P., Poltoratsky, V. & Vancurova, I. Bortezomib inhibits expression of TGF-\u03b21, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol \n                           194, 2942\u20132953, https:\/\/doi.org\/10.4049\/jimmunol.1402610 (2015).","journal-title":"J Immunol"},{"key":"13486_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/thoraxjnl-2011-200717","volume":"67","author":"GM Mutlu","year":"2012","unstructured":"Mutlu, G. M. et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-\u03b2(1) signalling. Thorax \n                           67, 139\u2013146, https:\/\/doi.org\/10.1136\/thoraxjnl-2011-200717 (2012).","journal-title":"Thorax"},{"key":"13486_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.semnephrol.2007.02.009","volume":"27","author":"EP B\u00f6ttinger","year":"2007","unstructured":"B\u00f6ttinger, E. P. TGF-beta in renal injury and disease. Semin Nephrol \n                           27, 309\u2013320, https:\/\/doi.org\/10.1016\/j.semnephrol.2007.02.009 (2007).","journal-title":"Semin Nephrol"},{"key":"13486_CR14","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/ndt\/gfs381","volume":"27","author":"M Yanagita","year":"2012","unstructured":"Yanagita, M. Inhibitors\/antagonists of TGF-\u03b2 system in kidney fibrosis. Nephrol Dial Transplant \n                           27, 3686\u20133691, https:\/\/doi.org\/10.1093\/ndt\/gfs381 (2012).","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"13486_CR15","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gft267","volume":"29","author":"I Loeffler","year":"2014","unstructured":"Loeffler, I. & Wolf, G. Transforming growth factor-\u03b2 and the progression of renal disease. Nephrol Dial Transplant \n                           29(Suppl 1), i37\u2013i45, https:\/\/doi.org\/10.1093\/ndt\/gft267 (2014).","journal-title":"Nephrol Dial Transplant"},{"key":"13486_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2169\/internalmedicine.55.5310","volume":"55","author":"W Yamaguchi","year":"2016","unstructured":"Yamaguchi, W. et al. Bence-Jones Protein \u03bb-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy. Intern Med \n                           55, 263\u2013268, https:\/\/doi.org\/10.2169\/internalmedicine.55.5310 (2016).","journal-title":"Intern Med"},{"key":"13486_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000346180","volume":"3","author":"L Huang","year":"2013","unstructured":"Huang, L., Scarpellini, A., Funck, M., Verderio, E. A. & Johnson, T. S. Development of a chronic kidney disease model in C57BL\/6 mice with relevance to human pathology. Nephron Extra \n                           3, 12\u201329, https:\/\/doi.org\/10.1159\/000346180 (2013).","journal-title":"Nephron Extra"},{"key":"13486_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0272-6386(12)80178-8","volume":"24","author":"M Depierreux","year":"1994","unstructured":"Depierreux, M., Van Damme, B., Vanden Houte, K. & Vanherweghem, J. L. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis \n                           24, 172\u2013180 (1994).","journal-title":"Am J Kidney Dis"},{"key":"13486_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0140-6736(93)92984-2","volume":"341","author":"JL Vanherweghem","year":"1993","unstructured":"Vanherweghem, J. L. et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet \n                           341, 387\u2013391 (1993).","journal-title":"Lancet"},{"key":"13486_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep12936","volume":"5","author":"YY Zhao","year":"2015","unstructured":"Zhao, Y. Y. et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep \n                           5, 12936, https:\/\/doi.org\/10.1038\/srep12936 (2015).","journal-title":"Sci Rep"},{"key":"13486_CR21","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1097\/01.ASN.0000088027.54400.C6","volume":"14","author":"J Mishra","year":"2003","unstructured":"Mishra, J. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol \n                           14, 2534\u20132543 (2003).","journal-title":"J Am Soc Nephrol"},{"key":"13486_CR22","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1074\/jbc.273.7.4135","volume":"273","author":"T Ichimura","year":"1998","unstructured":"Ichimura, T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem \n                           273, 4135\u20134142 (1998).","journal-title":"J Biol Chem"},{"key":"13486_CR23","doi-asserted-by":"publisher","first-page":"F1006","DOI":"10.1152\/ajprenal.00675.2009","volume":"298","author":"L Zhou","year":"2010","unstructured":"Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol \n                           298, F1006\u20131017, https:\/\/doi.org\/10.1152\/ajprenal.00675.2009 (2010).","journal-title":"Am J Physiol Renal Physiol"},{"key":"13486_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ajpath.2013.12.003","volume":"184","author":"X Qu","year":"2014","unstructured":"Qu, X. et al. Regulation of renal fibrosis by Smad3 Thr388 phosphorylation. Am J Pathol \n                           184, 944\u2013952, https:\/\/doi.org\/10.1016\/j.ajpath.2013.12.003 (2014).","journal-title":"Am J Pathol"},{"key":"13486_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nm.2144","volume":"16","author":"Y Li","year":"2010","unstructured":"Li, Y. et al. Epithelial cell cycle arrest in G2\/M mediates kidney fibrosis after injury. Nat Med \n                           16, 535\u2013143 (2010).","journal-title":"Nat Med"},{"key":"13486_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ndt\/gfu230","volume":"30","author":"G Canaud","year":"2015","unstructured":"Canaud, G. et al. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant \n                           30, 575\u201383 (2015).","journal-title":"Nephrol Dial Transplant"},{"key":"13486_CR27","first-page":"841","volume":"1","author":"L Yi-He","year":"2002","unstructured":"Yi-He, L. et al. PS-341, a Novel Proteasome Inhibitor, Induces Bcl-2 Phosphorylation and Cleavage in Association with G2-M Phase Arrest and Apoptosis 1 Supported in part by NIH Grants CA50270 and U01 CA76642. Mol Cancer Ther \n                           1, 841\u2013849 (2002).","journal-title":"Mol Cancer Ther"},{"key":"13486_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1440-1797.2010.01367.x","volume":"16","author":"T Sakairi","year":"2011","unstructured":"Sakairi, T. et al. Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology (Carlton) \n                           16, 76\u201386, https:\/\/doi.org\/10.1111\/j.1440-1797.2010.01367.x (2011).","journal-title":"Nephrology (Carlton)"},{"key":"13486_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.440","volume":"21","author":"F Rapino","year":"2013","unstructured":"Rapino, F., Naumann, I. & Fulda, S. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2\/M transition and MCL-1 degradation. Cell Death Dis. \n                           21, e925, https:\/\/doi.org\/10.1038\/cddis.2013.440 (2013).","journal-title":"Cell Death Dis."},{"key":"13486_CR30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/ndt\/gft022","volume":"28","author":"MA Aminzadeh","year":"2013","unstructured":"Aminzadeh, M. A., Nicholas, S. B., Norris, K. C. & Vaziri, N. D. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant \n                           28, 2038\u20132045, https:\/\/doi.org\/10.1093\/ndt\/gft022 (2013).","journal-title":"Nephrol Dial Transplant"},{"key":"13486_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/kisup.2014.21","volume":"4","author":"KObesity Sharma","year":"2014","unstructured":"Sharma, K. Obesity oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl (2011) \n                           4, 113\u2013117, https:\/\/doi.org\/10.1038\/kisup.2014.21 (2014).","journal-title":"Kidney Int Suppl (2011)"},{"key":"13486_CR32","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1681\/ASN.2004121055","volume":"16","author":"DT Wu","year":"2005","unstructured":"Wu, D. T. et al. TGF-beta concentration specifies differential signaling profiles of growth arrest\/differentiation and apoptosis in podocytes. J Am Soc Nephrol \n                           16, 3211\u201321 (2005).","journal-title":"J Am Soc Nephrol"},{"issue":"12(4)","key":"13486_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176096","volume":"17","author":"KL Bailey","year":"2017","unstructured":"Bailey, K. L. et al. TGF\u03b2\/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells. PLoS One. \n                           17(12(4)), e0176096, https:\/\/doi.org\/10.1371\/journal.pone.0176096 (2017).","journal-title":"PLoS One."},{"key":"13486_CR34","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1681\/ASN.2005121366","volume":"17","author":"P Fu","year":"2006","unstructured":"Fu, P. et al. Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol \n                           17, 3105\u20133114, https:\/\/doi.org\/10.1681\/ASN.2005121366 (2006).","journal-title":"J Am Soc Nephrol"},{"key":"13486_CR35","first-page":"587","volume":"12","author":"K Tashiro","year":"2003","unstructured":"Tashiro, K. et al. Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med \n                           12, 587\u2013592 (2003).","journal-title":"Int J Mol Med"},{"key":"13486_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000368454","volume":"39","author":"A Malik","year":"2014","unstructured":"Malik, A. et al. Aristolochic acid induced suicidal erythrocyte death. Kidney Blood Press Res \n                           39, 408\u2013419, https:\/\/doi.org\/10.1159\/000368454 (2014).","journal-title":"Kidney Blood Press Res"},{"key":"13486_CR37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/toxsci\/kfv125","volume":"147","author":"YH Chen","year":"2015","unstructured":"Chen, Y. H., Chou, C. Y. & Sun, C. Y. Impairment of the Cellular Distribution and Stability of the Erythropoietin Receptor Through the Direct Targeting of Aristolochic Acid. Toxicol Sci \n                           147, 246\u2013254, https:\/\/doi.org\/10.1093\/toxsci\/kfv125 (2015).","journal-title":"Toxicol Sci"},{"key":"13486_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/ki.1993.362","volume":"44","author":"PH Maxwell","year":"1993","unstructured":"Maxwell, P. H. et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int \n                           44, 1149\u20131162 (1993).","journal-title":"Kidney Int"},{"key":"13486_CR39","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI57301","volume":"121","author":"N Asada","year":"2011","unstructured":"Asada, N. et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest \n                           121, 3981\u20133990, https:\/\/doi.org\/10.1172\/JCI57301 (2011).","journal-title":"J Clin Invest"},{"key":"13486_CR40","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med \n                           14, 748\u2013755, https:\/\/doi.org\/10.1038\/nm1763 (2008).","journal-title":"Nat Med"},{"key":"13486_CR41","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","volume":"86","author":"MJ Everly","year":"2008","unstructured":"Everly, M. J. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation \n                           86, 1754\u20131761, https:\/\/doi.org\/10.1097\/TP.0b013e318190af83 (2008).","journal-title":"Transplantation"},{"key":"13486_CR42","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","volume":"19","author":"M Mohty","year":"2013","unstructured":"Mohty, M., Brissot, E., Savani, B. N. & Gaugler, B. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant \n                           19, 1416\u20131420, https:\/\/doi.org\/10.1016\/j.bbmt.2013.05.011 (2013).","journal-title":"Biol Blood Marrow Transplant"},{"key":"13486_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejphar.2007.11.050","volume":"581","author":"H Chen","year":"2008","unstructured":"Chen, H. et al. Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia\/reperfusion injury. Eur J Pharmacol \n                           581, 306\u2013314, https:\/\/doi.org\/10.1016\/j.ejphar.2007.11.050 (2008).","journal-title":"Eur J Pharmacol"},{"key":"13486_CR44","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1681\/ASN.2009121295","volume":"21","author":"SS Yang","year":"2010","unstructured":"Yang, S. S. et al. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol \n                           21, 1868\u20131877, https:\/\/doi.org\/10.1681\/ASN.2009121295 (2010).","journal-title":"J Am Soc Nephrol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13486-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:55:10Z","timestamp":1671796510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["13486"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-13486-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]},"assertion":[{"value":"4 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13086"}}